• Find people
• Intranet

News / Press release

• 06/10/2011 - Press release

  Drug design enters a new dimension

  Certara , a US-based company and a leader in the provision of translational medicine services and solutions, is set to be the exclusive distributor of the software developed by Chemotargets the first spin-off of the IMIM (Instituto de Investigación Hospital del Mar, 'Hospital del Mar Research Institute') dedicated to the design of new drugs.

  Més informació "Drug design enters a new dimension"

• 19/09/2011 - Press release

  A study shows that patients with COPD do not show muscular destruction until very advanced stages of the disease

  A team of researchers from the Hospital del Mar and IMIM, as well as from CIBER for Respiratory Diseases (CIBERES) – Carlos III Health Institute – Ministry of Science and Innovation- has lead a study proving that patients with severe COPD do not present muscular destruction until very advanced stages of the disease, especially when they still maintain a good muscle mass.

  Més informació "A study shows that patients with COPD do not show muscular destruction until very advanced stages of the disease"

• 12/09/2011 - Press release

  New Leads on the Genetic Origin of High Blood Pressure

  The International Consortium for Blood Pressure genome-wide association Studies (ICBP), an international project in which researchers from the IMIM (Hospital del Mar Research Institute) have participated as the only Spanish researchers, has identified 29 loci or genetic characteristics, 16 of which are new, associated with the risk of presenting with high blood pressure in a population of European origin

  Més informació "New Leads on the Genetic Origin of High Blood Pressure"

• 9/09/2011 - Press release

  A study confirms the prognostic value of a new therapeutic target against breast cancer

  Researchers from the Hospital del Mar Oncology Department and the Cancer Research Programme of its research Institute, the ‘IMIM’, have confirmed the prognostic value of a new therapeutic target, the PARP1 protein, in breast cancer patients. This finding, which was published today in the Annals of Oncology, was achieved in partnership with the Jiménez-Díaz Foundation in Madrid and the Hospital Clínico in Valencia

  Més informació "A study confirms the prognostic value of a new therapeutic target against breast cancer"

• 08/09/2011 - Press release

  The Size and Burden of Mental Disorders and Other Disorders of the Brain in Europe – It’s worse than we thought

  A major landmark study released a few days ago by the European College of Neuropsychopharmacology (ECNP) in which IMIM (Hospital del Mar Research Institute) has participated, sheds new light on the state of Europe’s mental and neurological health.

  Més informació "The Size and Burden of Mental Disorders and Other Disorders of the Brain in Europe – It’s worse than we thought"

• 06/06/2011 - Press release

  A major step in molecular simulation - key to designing new drugs

  Researchers at Hospital del Mar Research Institute (IMIM) and Pompeu Fabra University (UPF) have successfully reproduced and reconstructed the complete process of a small molecule binding with its target protein. This advance enables the drug's affinity and binding level with the protein to be calculated as well as understanding the interactions established by the drug in order to act, thus moving towards safer and more efficient design of new drugs.

  Més informació "A major step in molecular simulation - key to designing new drugs"

• 27/05/2011 - Press release

  Semantic 'lego': an information framework to drive drug discovery.

  A new consortium of European organisations unite to support next generation drug discovery by providing a single view across data sources, bringing the semantic web to drug discovery.

  Més informació "Semantic 'lego': an information framework to drive drug discovery."

• 26/05/2011 - Press release

  An IMIM study is the key to the approval of a health claim by the European Food Safety Authority (EFSA)

  At the request of the European Commission, the European Food Safety Authority (EFSA) has issued a scientific opinion on a food product, namely, about the health properties of olive oil. This has been possible thanks to the contribution of the cardiovascular risk and nutrition research group at the IMIM (Hospital del Mar Research Institute).

  Més informació "An IMIM study is the key to the approval of a health claim by the European Food Safety Authority (EFSA)"

• 12/04/2011 - Press release

  High blood pressure, dyslipidaemia and obesity: the most prevalent cardiovascular risk factors in Spain

  High blood pressure, dyslipidaemia and obesity are the three most prevalent cardiovascular risk factors among Spaniards aged between 35 and 74 years. In addition, these factors occur most commonly in the autonomous regions of Extremadura, the Canaries and Andalusia. Here are some of the conclusions reached by the DARIOS Study.

  Més informació "High blood pressure, dyslipidaemia and obesity: the most prevalent cardiovascular risk factors in Spain"

• 06/03/2011 - Press release

  New leads on the genetic origin of coronary artery disease

  An International study to be published online on the 6th March in the prestigious journal Nature Genetics identifies 13 new genetic characteristics associated with coronary artery disease.Genetic factors are thought to explain about 40% of the risk of the population presenting with coronary artery disease.

  Més informació "New leads on the genetic origin of coronary artery disease"